MedPath

A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer

Not Applicable
Conditions
Carcinoma, Hepatocellular
Registration Number
NCT00563095
Lead Sponsor
Hospital Authority, Hong Kong
Brief Summary

Primary: To compare the efficacy of TACE and TAIE.

Secondary: To compare the side effects of TACE and TAIE.

The outcome measurements include survival benefit and tumour regression induced by the two therapies.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Confirmed hepatocellular carcinoma not suitable for surgery
Exclusion Criteria
  • Portal vein thrombosis
  • Severe arteriovenous shunt
  • Bilirubin level > 50 umol/mL
  • Prothrombin time > 5 seconds

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
regression of tumour sizeassessment every 6 months
Secondary Outcome Measures
NameTimeMethod
side effectsevery treatment given every 8 - 12 weeks

Trial Locations

Locations (1)

Queen Mary Hospital

🇨🇳

Hong Kong, China

© Copyright 2025. All Rights Reserved by MedPath